Federal Judge Bars Doctor's Testimony On Future Medical Costs, Causation To Illness
SAN JUAN, Puerto Rico - A doctor may not testify on claims of future medical expenses and alleged causation between benzene and chronic myelogenous leukemia (CML), a Puerto Rico federal judge ruled Jan. 8 (Gerardo Campos, et al. v. Safety-Kleen Systems, Inc., et al., No. 12-1529, D. Puerto Rico; 2016 U.S. Dist. LEXIS 2474). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - January 21, 2016 Category: Medical Law Source Type: news
Chemotherapy for Germ Cell Tumor May Spur CMLChemotherapy for Germ Cell Tumor May Spur CML
Findings raise the question of a causal link between etoposide and/or platinum-containing chemotherapy and the development of chronic myelogenous leukemia (CML). Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Sun Pharma gets boost with US FDA approval for Gleevec
Sun Pharmaceutical announced it received approval from the US FDA for generic copies of Gleevec, a drug that treats chronic myeloid leukemia. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 4, 2015 Category: Pharmaceuticals Source Type: news
UCLA study identifies potential therapeutic targets for metastatic prostate cancer
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have pinpointed five specific enzymes called protein kinases that play a role when prostate cancer spreads to bone. The discovery could point the way toward new drugs that slow or stop prostate cancer from spreading.
The findings, which were published in the journal Proceedings of the National Academy of Sciences, are particularly important because in the vast majority of men whose prostate cancer spreads, or metastasizes, the cancer reaches the bone and is much more difficult to treat. When the disease is confined to the ...
Source: UCLA Newsroom: Health Sciences - December 2, 2015 Category: Universities & Medical Training Source Type: news
NCCN Unveils Evidence Blocks for CML and Multiple Myeloma
New visual tool illustrates five dimensions of value within NCCN Guidelines
SAN FRANCISCO, Calif., (October 16, 2105) - The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers, today unveiled its new value initiative-the NCCN Evidence Blocks™, published within new versions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myelogenous Leukemia (CML) and Multiple Myeloma.
'I... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - October 18, 2015 Category: Cancer & Oncology Source Type: news
Tips for Managing CV Toxicity With TKIs in Leukemia PatientsTips for Managing CV Toxicity With TKIs in Leukemia Patients
A new review covers cardiovascular (CV) toxicity for patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitors (TKIs), and provides practical recommendations on management. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Dying father denied life-saving cancer drug by the NHS in postcode lottery scandal
Khalid Younis, 43, from Birmingham, suffers from Chronic Myeloid Leukaemia and has become resistant to all drugs. He believes the drug ponatinib would be his last hope of a cure. (Source: the Mail online | Health)
Source: the Mail online | Health - September 17, 2015 Category: Consumer Health News Source Type: news
Diabetes Drug Appears to Eliminate Residual CMLDiabetes Drug Appears to Eliminate Residual CML
Adding the diabetes drug pioglitazone to standard therapy for chronic myeloid leukemia eradicated cancer stem cells in three patients with residual disease. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Could Common Diabetes Drugs Help Fight Leukemia?
Combining glitazones with standard treatment improved survival in small studySource: HealthDay
Related MedlinePlus Pages: Chronic Myeloid Leukemia, Diabetes Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 2, 2015 Category: Consumer Health News Source Type: news
How do harmful chronic myelogenous leukemia stem cells obtain their nutrients?
Medical researchers have found a novel nutrient uptake process that maintains the activity of murine chronic myelogenous leukemia (CML) stem cells. Pharmacological inhibition of nutrient uptake decreased CML stem cell activity. Certain nutrients support CML stem cell activity in vivo, thus pointing towards a potential therapeutic target for CML therapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 26, 2015 Category: Science Source Type: news
Medical News Today: Bosutinib is well-suited for older patients with chronic myeloid leukemia
In our final report from the 20th Congress of the European Hematology Association, we look at the results of a clinical trial for the tyrosine kinase inhibitor bosutinib. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 4, 2015 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Big data analysis platform to unveil gene interactions in cancer
A breakthrough in cancer genomics has been achieved by developing a novel big data analysis platform for analyzing the interactions among genes. The analysis platform unveils the unregulated patterns of gene network in cancer and discovers potential diagnostic and therapeutic target genes, Nucleophosmin (NPM1) and its associated genes, in Chronic Myelogenous Leukemia (CML). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 23, 2015 Category: Science Source Type: news
PolyU develops big data analysis platform to unveil gene interactions in cancer
(The Hong Kong Polytechnic University ) The Hong Kong Polytechnic University (PolyU) has achieved a breakthrough in the cancer genomics by developing a novel big data analysis platform for analyzing the interactions among genes. The analysis platform unveils the unregulated patterns of gene network in cancer and discovers potential diagnostic and therapeutic target genes, Nucleophosmin (NPM1) and its associated genes, in Chronic Myelogenous Leukemia (CML). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 23, 2015 Category: Global & Universal Source Type: news
New treatment for rare forms of leukaemia available across Scotland
ARIAD today welcomed the Scottish Medicine Consortium’s (SMC) acceptance to use Iclusig® (ponatinib) as a clinical and cost effective treatment for all phases of chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), in accordance with Iclusig’s licenced indication. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 27, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Haematology Oncology Patient care chronic myeloid leukaemia Latest News philadelphia chromosome positive ponatinib Source Type: news
Anticancer drug can spur immune system to fight infection
Imatinib, an example of a 'targeted therapy' against cancer, or related drugs might be tools to fight a variety of infections, scientists say. Imatinib, is an example of a "targeted therapy" against certain types of cancer. It blocks tyrosine kinase enzymes, which are dysregulated in cancers such as chronic myelogenous leukemia and gastrointestinal stromal tumors. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 1, 2015 Category: Science Source Type: news
